Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
blinatumomab (blincyto) (1 trial)
bortezomib (velcade) (1 trial)
brigatinib (alunbrig) (1 trial)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)
Trials (3 total)
Trial APIs (3 total)